GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Zydus Lifesciences Ltd

Zydus Lifesciences Reports Q2 FY27 Standalone Net Profit of INR 7,145 Million

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 04 Nov 2026, 12:24 PM IST  ·  BSE ID: 5fa80133-baaa-49f5-8b5b-9f938e143913
View Original BSE Filing (PDF)
💡
In Simple Terms
Zydus Lifesciences announced its latest financial results, showing a net profit of INR 7,145 Million for the recent quarter.
🤖 AI Summary
  • Zydus Lifesciences reported standalone net profit of INR 7,145 Million for the quarter ended September 30, 2026.
  • Total revenue from operations reached INR 34,820 Million for Q2 FY27.
  • Other income for the quarter included dividend of INR 220 Million from subsidiaries and joint ventures.
  • The company recognized an exceptional item of INR 19 Million in Q2 FY27.
  • Profit before tax for the quarter was INR 9,621 Million.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Total revenue from operations (Q2 FY27)
34,820 INR Million
Total revenue from operations (Q2 FY26)
28,712 INR Million
Net Profit for the period (Q2 FY27)
7,145 INR Million
Net Profit for the period (Q2 FY26)
11,566 INR Million
Exceptional item (Q2 FY27)
19 INR Million
🏢 How This Affects the Company
📈
Business Impact
The increase in sales of products to INR 33,623 Million in Q2 FY27 suggests ongoing demand for the company's offerings.
💰
Financial Impact
Net Profit for Q2 FY27 was INR 7,145 Million, contributing to a half-year net profit of INR 10,541 Million. The company incurred INR 19 Million in exceptional items related to asset damage from torrential rains.
⚙️
Operational Impact
Torrential rains in July 2026 impacted some Ahmedabad manufacturing facilities, causing damage to assets and inventories. The company has lodged insurance claims for INR 373 Million.
⚠️
Risk Impact
Operational disruptions due to natural events, as experienced in July 2026, highlight business continuity risks, though the company has insurance coverage for such losses.
👥 What This Means For Shareholders
✅
Action Required
No action required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as the company's Q2 FY27 standalone financial performance, with a net profit of INR 7,145 Million, directly impacts the company's financial standing.
🔍
Management Signal
The Board's approval of the unaudited financial results and limited review report signals adherence to regulatory disclosure requirements and financial reporting transparency.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — monitor revenue from operations and net profit trend.
Insurance claim status — track recoveries for asset damage from torrential rains.
Impact of New Labour Codes — watch for further assessments and financial implications.
MEDIUM RISK Exceptional items and lower other income compared to previous year indicates some operational and financial volatility.
💡 Investor Takeaway
Zydus Lifesciences reported Q2 FY27 standalone net profit of INR 7,145 Million, an increase from INR 3,396 Million in Q1 FY27. Total revenue from operations reached INR 34,820 Million for the quarter. Exceptional items amounted to INR 19 Million.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Revenue from operations for Q2 FY27 grew to INR 34,820 Million from INR 28,712 Million in Q2 FY26.
  • The company recorded a Net Profit of INR 7,145 Million for Q2 FY27, compared to INR 3,396 Million in the preceding quarter.

⚠️ Concerns

  • Other income for Q2 FY27 was INR 1,646 Million, significantly lower than INR 5,415 Million in Q2 FY26.
  • The company reported an exceptional item of INR 19 Million in Q2 FY27 due to asset damage from torrential rains at manufacturing facilities.
📅 Company Track Record
Zydus Lifesciences announced a board meeting on May 19, 2026, for Q4 FY26 results and dividend, as per a filing on May 8, 2026. This indicates a consistent reporting schedule for financial performance and shareholder returns.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is Zydus Lifesciences' standalone net profit for Q2 FY27?
Zydus Lifesciences reported a standalone net profit of INR 7,145 Million for the quarter ended September 30, 2026 (Q2 FY27).
What was Zydus Lifesciences' total revenue from operations in Q2 FY27?
Total revenue from operations for Zydus Lifesciences was INR 34,820 Million for the quarter ended September 30, 2026.
Did Zydus Lifesciences report any exceptional items in Q2 FY27?
Yes, Zydus Lifesciences reported an exceptional item of INR 19 Million for the quarter ended September 30, 2026, related to asset damage from torrential rains.
How much dividend was received from subsidiaries in Q2 FY27 for Zydus Lifesciences?
Other income for Q2 FY27 included dividend from subsidiaries and joint ventures amounting to INR 220 Million.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.